Another phase 2 randomized clinical trial in patients with AD investigated the effectiveness of Neudexta® (Jenson Pharmaceutical Services Limited), also referred to as dextromethorphan, which shows an affinity for S1R and quinidine. Here, TMBIM4 is linked to Alzheimer disease.